Low antituberculosis drug concentrations in patients with AIDS

OBJECTIVE: To determine the frequency and magnitude of below normal apparent peak serum concentrations for antituberculosis drugs in patients with AIDS and CD4 cell counts less than 200 cells/mm3. We also explored the data for potential relationships between response variables and patient characteristics. DESIGN: Prospective study of consecutive patients seen in tuberculosis clinics. SETTING: Five urban tuberculosis clinics in four major metropolitan areas. PARTICIPANTS: Twenty-six patients diagnosed with HIV infection and receiving treatment for active tuberculosis were eligible. MAIN OUTCOME MEASURES: After 2 weeks or more of therapy, blood was collected 2 hours after observed doses of the antituberculosis drugs. Serum samples were frozen, shipped to National Jewish Center in Denver, and analyzed by HPLC or GC. Serum concentrations were compared with the proposed normal ranges. Data were analyzed to determine correlations between antituberculosis drug serum concentrations and patient characteristics. RESULTS: Low-2-hour serum concentrations were common for antituberculosis drugs, particularly rifampin and ethambutol. Absorption of isoniazid was generally high. Potential drug-drug interactions were found between rifampin and fluconazole (fluconazole appears to increase rifampin concentrations) and between pyrazinamide and zidovudine (zidovudine may lower pyrazinamide concentrations). Patients receiving pyrazinamide had lower rifampin concentrations than those not receiving pyrazinamide. CONCLUSIONS: Low antituberculosis drug serum concentrations occur frequently during the treatment of tuberculosis in patients with AIDS. Additional research is required for patients with drug-resistant tuberculosis, and to clarify the nature of the potential drug-drug interactions.

This article has been cited by other articles:

				B. Mathema, N. E. Kurepina, P. J. Bifani, and B. N. Kreiswirth Molecular Epidemiology of Tuberculosis: Current Insights Clin. Microbiol. Rev., October 1, 2006; 19(4): 658 - 685. [Abstract] [Full Text] [PDF]

				H. McIlleron, P. Wash, A. Burger, J. Norman, P. I. Folb, and P. Smith Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1170 - 1177. [Abstract] [Full Text] [PDF]

				S. M. Graham, D. J. Bell, S. Nyirongo, R. Hartkoorn, S. A. Ward, and E. M. Molyneux Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., February 1, 2006; 50(2): 407 - 413. [Abstract] [Full Text] [PDF]

				P. Gurumurthy, G. Ramachandran, A. K. Hemanth Kumar, S. Rajasekaran, C. Padmapriyadarsini, S. Swaminathan, S. Bhagavathy, P. Venkatesan, L. Sekar, A. Mahilmaran, et al. Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4473 - 4475. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				E. D Chan and M. D Iseman Current medical treatment for tuberculosis BMJ, November 30, 2002; 325(7375): 1282 - 1286. [Full Text] [PDF]

				J. E. Conte Jr., J. A. Golden, M. McQuitty, J. Kipps, S. Duncan, E. McKenna, and E. Zurlinden Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2358 - 2364. [Abstract] [Full Text] [PDF]

				J. E. Conte Jr., J. A. Golden, J. Kipps, E. T. Lin, and E. Zurlinden Effects of AIDS and Gender on Steady-State Plasma and Intrapulmonary Ethambutol Concentrations Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2891 - 2896. [Abstract] [Full Text]

				W. J. BURMAN and B. E. JONES Treatment of HIV-related Tuberculosis in the Era of Effective Antiretroviral Therapy Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 7 - 12. [Abstract] [Full Text] [PDF]

				J. M. Conry Significant Drug Interactions in the HIV Patient Journal of Pharmacy Practice, December 1, 2000; 13(6): 499 - 514. [Abstract] [PDF]

				J. E. Conte Jr., J. A. Golden, M. McQuitty, J. Kipps, E. T. Lin, and E. Zurlinden Effects of AIDS and Gender on Steady-State Plasma and Intrapulmonary Ethionamide Concentrations Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1337 - 1341. [Abstract] [Full Text]

				M. K. Lacy, D. P. Nicolau, C. H. Nightingale, A. Geffken, R. Teng, J. Vincent, and R. Quintiliani Oral Bioavailability and Pharmacokinetics of Trovafloxacin in Patients with AIDS Antimicrob. Agents Chemother., December 1, 1999; 43(12): 3005 - 3007. [Abstract] [Full Text]

				J. E. Conte Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden Intrapulmonary Concentrations of Pyrazinamide Antimicrob. Agents Chemother., June 1, 1999; 43(6): 1329 - 1333. [Abstract] [Full Text]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				L. SANDMAN, N. W. SCHLUGER, A. L. DAVIDOW, and S. BONK Risk Factors for Rifampin-monoresistant Tuberculosis . A Case-Control Study Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 468 - 472. [Abstract] [Full Text]

				R. RIDZON, C. G. WHITNEY, M. T. MCKENNA, J. P. TAYLOR, S. H. ASHKAR, A. T. NITTA, S. M. HARVEY, S. VALWAY, C. WOODLEY, R. COOKSEY, et al. Risk Factors for Rifampin Mono-resistant Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1881 - 1884. [Abstract] [Full Text] [PDF]